Philadelphia, PA (October 28, 2020) – Oncoceutics, Inc. announced today that the first patient has been treated in a first-in-human…
Browsing: General
Ramaprasad Srinivasan, M.D., Ph.D. of the NIH National Cancer Institute speaks about the ESMO 2020 abstract Phase II study of…
Marcia S. Brose, MD, Ph.D. of the Pearlman School of Medicine at The University of Pennsylvania speaks on the ESMO…
Marcia S. Brose, MD, Ph.D. of the Pearlman School of Medicine at The University of Pennsylvania discusses the ESMO 2020…
Ian Chau, MD from Royal Marsden Hospital speaks about the ESMO 2020 abstract Initial safety and efficacy findings with bavituximab…
Ian Chau, MD from Royal Marsden Hospital discusses the ASCO abstract Initial safety run-in findings with bavituximab plus pembrolizumab in…
Timothy A. Yap, MD of MD Anderson discusses ESMO 2020 Poster: Rucaparib + Sacituzumab Govitecan: Initial Data From the Phase…
Dr. Zeynep Zengin, post-doctoral fellow at City of Hope discusses the ESMO Virtual Congress 2020: Assessment of Circulating Cell-Free Tumor…
Professor Ray McDermott of St. Vincent University Hospital and Tallaght Hospital, Ireland discusses ESMO – Survival benefits of larotrectinib in…
Peter R. Galle, MD of University Medical Center Mainz discusses his ESMO 2020 abstract – Updated results of a phase…
Jacob J. Adashek, DO of the Moffitt Cancer Center explains the ESMO 2020 Abstract – Personalized molecularly matched therapies for…
Lillian Siu, MD of the Princess Margaret Cancer Centre discusses ESMO 2020 abstract #524O, Proffered Paper: Initial Results of a…
Eric Jonasch, MD The University of Texas MD Anderson Cancer Center ASCO 2020 Phase II study of the oral HIF-2α…
S. Michelle Shiller, DO, AP/CP, MGP at PathGroup discusses how the Pan-Cancer Consortium Moves to Clarify and Promote Consistent Use…
Nick Smith-Stanley, MBA, Associate Director of Administration & Strategic Planning of the LIVESTRONG Cancer Institutes, Dell Medical School speaks about…
Greg Hiebert, Leadership Educator, Coach, and Consultant of Leadership Forward discusses Leadership Resilience and Post Traumatic Growth & Live. Great…
David R. Gandara, MD at MDAnderson discusses Guardant Health’s FDA approval of the Guardant360 CDx which delivers critical genomic information…
Aurélien Marabelle, MD at Gustave Roussy discusses the FDA Approval of Second Biomarker-Based Indication for Pembrolizumab (KEYTRUDA) The FDA issued…
Wendy Stock, MD of University of Chicago receives 2020 Mentor Award Recipient The Anjuli Seth Nayak Professor of Leukemia at…
Timothy A. Yap, MD from MD Anderson discusses an abstract from Journal of Clinical Oncology entitled Phase I Trial of…
Professor Galina Velikova, MD of the Leeds Institute of Medical Research discusses the ASCO abstract Phase III randomized controlled trial…
Jingxuan Zhao, MPH @AmercianCancer #ASCO20 Health insurance status and cancer stage at diagnosis and survival in the United States Bottom…
Manisha H Shah, MD of The James Ohio State University Comprehensive Cancer Center discusses the Efficacy of Selpercatinib in RET-Altered…
Ben George, MD from Froedtert & Medical College discusses an ASCO 2020 abstract entitied A phase I, first-in-human, open-label, dose‑escalation,…
Jan Schellens, MD, CMO Byondis discusses the Phase I Study of Antibody-Drug Conjugate SYD1875. 11 August 2020, Nijmegen, The Netherlands,…
Nicolo Manaresi, Ph.D. Chief Scientific Officer of M Silicon Biosystems gives an overview of Two Studies Presented at AACR 20…
Allison Huegel, COO AxoProtego and Ahmet Hoke, MD, Ph.D. Johns Hopkins Medicine gives an overview of AxoProtego Therapeutics Announces Novel…
David Spetzler, M.S., Ph.D., MBA, President and Chief Scientific Officer of Caris Life Sciences discusses their Partners with Elevation Oncology…
Babar Bashir, MD from Jefferson Health discussed an ASCO 2020 abstract entitled BT5528-100 phase I/II study of the safety, pharmacokinetics,…
Patrick Glen Pilie, MD MD Anderson discusses an ASCO 2020 abstract entitled Identifying Functional Loss of ATM Gene In Patients…
Istvan Petak, MD #ASCO20 Oncompass Medicine SHIVA01 Trial Update Context: Precision oncology demands that individual molecular pathomechanisms be identified in…
Christian Marsolais @Theratech_ #AACR20 NEW DATA SHOW THERATECHNOLOGIES’ SORT1+ TECHNOLOGY IS EFFECTIVE IN MANY TREATMENT-RESISTANT CANCERS The optimisation of the…
Ignacio Garrido-Laguna, MD at Huntsman Cancer Institute discusses the ASCO 2020 abstract entitled A phase I, first-in-human, open-label, dose‑escalation, safety,…
Wilson H. Miller, MD Jewish General Hospital discusses an ASCO 2020 abstract entitled A phase Ib study of oral Chk1…
Filip Janku, MD at MD Anderson discusses an ASCO 2020 abstract entitled Phase I study of IM156, a novel potent…
Scott Tomlins, MD, Ph.D. Co-Founder, and Chief Scientific Officer – Strata discusses the Strata Oncology Partners with Elevation Oncology to…
Audrey Guth, Nanny Angel Network – Astellas Oncology discusses Astellas Oncology Opens Annual C3 Prize® Call for Entries to Award…
Astrid Margossian, MD @SEngineMedicine discusses an ASCO 2020 poster entitled Predictive value of a CLIA-approved organoid based drug sensitivity test…
Mohamed Alaa Gouda, MD MD Anderson discusses Genomically informed longitudinal monitoring of circulating tumor DNA (ctDNA) to predict outcomes of…
Mohamed Alaa Gouda, MD MD Anderson discusses Genomically informed longitudinal monitoring of circulating tumor DNA (ctDNA) to predict outcomes of…
Mark Stroh, Ph.D. – CytomX Therapeutics discusses CX-2009 Abstract – a PROBODY drug conjugate targeting CD71 (transferrin receptor): Results from…
Mark Stroh, Ph.D. – CytomX Therapeutics discusses CX-2009 Abstract – a PROBODY drug conjugate targeting CD71 (transferrin receptor): Results from…
Mark Stroh, Ph.D. – CytomX Therapeutics discusses CX-2009 Abstract – a PROBODY drug conjugate targeting CD71 (transferrin receptor): Results from…
In this edition of The Onco’Zine Brief Peter Hofland, Ph.D. talks with Cristian Massacesi, MD, Senior Vice President, Head of…
Robert Epstein, MD – Epstein Health, LLC. – discusses Real-world burden of chemotherapy-induced myelosuppression: Results of a U.S. online survey…
Robert Epstein, MD – Epstein Health, LLC. – discusses Real-world burden of chemotherapy-induced myelosuppression: Results of a U.S. online survey…
Robert Epstein, MD – Epstein Health, LLC. – discusses Real-world burden of chemotherapy-induced myelosuppression: Results of a U.S. online survey…
Radek Spisek, Ph.D. SOTIO discusses SO-C101 displays strong anti-tumor effect in TC-1 and TRAMP-C2 tumor mice and in combination with…
Radek Spisek, Ph.D. SOTIO discusses SO-C101 displays strong anti-tumor effect in TC-1 and TRAMP-C2 tumor mice and in combination with…
Radek Spisek, Ph.D. SOTIO discusses SO-C101 displays strong anti-tumor effect in TC-1 and TRAMP-C2 tumor mice and in combination with…